Radoslaw Kaczmarek

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1477658/publications.pdf

Version: 2024-02-01

45	530	687363 13	713466 21
papers	citations	h-index	g-index

50	50	50	673
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Molecular Revolution in the Treatment of Hemophilia. Molecular Therapy, 2020, 28, 997-1015.	8.2	66
2	Erythrocyte glycophorins as receptors for Plasmodium merozoites. Parasites and Vectors, 2019, 12, 317.	2.5	43
3	A Single Point Mutation in the Gene Encoding Gb3/CD77 Synthase Causes a Rare Inherited Polyagglutination Syndrome. Journal of Biological Chemistry, 2012, 287, 38220-38230.	3.4	40
4	How glycosylation affects glycosylation: the role of N-glycans in glycosyltransferase activity. Glycobiology, 2020, 30, 941-969.	2.5	37
5	The patientâ€™s view on rare disease trial design â€“ a qualitative study. Orphanet Journal of Rare Diseases, 2019, 14, 31.	2.7	34
6	P1PK, GLOB, and FORS Blood Group Systems and GLOB Collection: Biochemical and Clinical Aspects. Do We Understand It All Yet?. Transfusion Medicine Reviews, 2014, 28, 126-136.	2.0	33
7	Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?. Haemophilia, 2020, 26, 931-933.	2.1	24
8	Human Gb3/CD77 synthase reveals specificity toward two or four different acceptors depending on amino acid at position 211, creating Pk, P1 and NOR blood group antigens. Biochemical and Biophysical Research Communications, 2016, 470, 168-174.	2.1	20
9	The Baculovirus-Expressed Binding Region of Plasmodium falciparum EBA-140 Ligand and Its Glycophorin C Binding Specificity. PLoS ONE, 2015, 10, e0115437.	2.5	19
10	The Gerbich blood group system: old knowledge, new importance. Transfusion Medicine Reviews, 2018, 32, 111-116.	2.0	16
11	Safety and efficacy of emicizumab and other novel agents inÂnewborns andÂinfants. Haemophilia, 2019, 25, e334-e335.	2.1	16
12	Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia, 2020, 26, 443-449.	2.1	15
13	Management of COVIDâ€19â€associated coagulopathy in persons with haemophilia. Haemophilia, 2021, 27, 41-48.	2.1	14
14	Eliminating Panglossian thinking in development of AAV therapeutics. Molecular Therapy, 2021, 29, 3325-3327.	8.2	12
15	Evaluation of an amino acid residue critical for the specificity and activity of human Gb3/CD77 synthase. Glycoconjugate Journal, 2016, 33, 963-973.	2.7	11
16	The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. Health Policy, 2018, 122, 1287-1294.	3.0	11
17	Single nucleotide polymorphisms in A4GALT spur extra products of the human Gb3/CD77 synthase and underlie the P1PK blood group system. PLoS ONE, 2018, 13, e0196627.	2.5	11
18	B cellâ€“activating factor modulates the factor VIII immune response in hemophilia A. Journal of Clinical Investigation, 2021, 131, .	8.2	10

#	Article	IF	Citations
19	CD1: A Singed Cat of the Three Antigen Presentation Systems. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 201-214.	2.3	9
20	Human Gb3/CD77 synthase produces P1 glycotope-capped N-glycans, which mediate Shiga toxin 1 but not Shiga toxin 2 cell entry. Journal of Biological Chemistry, 2021, 296, 100299.	3.4	9
21	Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518.	2.1	9
22	Treatment-induced hemophilic thrombosis?. Molecular Therapy, 2022, 30, 505-506.	8.2	7
23	Plasmodium reichenowi EBA-140 merozoite ligand binds to glycophorin D on chimpanzee red blood cells, shedding new light on origins of Plasmodium falciparum. Parasites and Vectors, 2017, 10, 554.	2.5	6
24	RT-qPCR analysis of human melanoma progression-related genes â€“ A novel workflow for selection and validation of candidate reference genes. International Journal of Biochemistry and Cell Biology, 2018, 101, 12-18.	2.8	6
25	Studies of a Murine Monoclonal Antibody Directed against DARC: Reappraisal of Its Specificity. PLoS ONE, 2015, 10, e0116472.	2.5	6
26	Baculovirus-expressed Plasmodium reichenowi EBA-140 merozoite ligand is host specific. Parasitology International, 2016, 65, 708-714.	1.3	5
27	Do adventitious viruses carried by insect cell lines producing <scp>AAV</scp> vectors pose a safety risk in gene therapy?. Haemophilia, 2018, 24, 843-844.	2.1	5
28	Bacterially expressed truncated F2 domain of Plasmodium falciparum EBA-140 antigen can bind to human erythrocytes.. Acta Biochimica Polonica, 2012, 59, .	0.5	5
29	Gene therapy â€“ are we ready now?. Haemophilia, 2022, 28, 35-43.	2.1	5
30	Ludwik Hirszfeld: A pioneer of transfusion and immunology during the world wars and beyond. Vox Sanguinis, 2022, 117, 467-475.	1.5	4
31	One of the two N-glycans on the human Gb3/CD77 synthase is essential for its activity and allosterically regulates its function. Biochemical and Biophysical Research Communications, 2022, 617, 36-41.	2.1	3
32	Genetyczne podstawy syntezy cukrowych antygenÃ³w grupowych krwi. Acta Haematologica Polonica, 2013, 44, 251-259.	0.3	2
33	Professor Elwira Lisowska Celebrates Her 90th Birthday. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 1.	2.3	2
34	Bacterially expressed truncated F2 domain of Plasmodium falciparum EBA-140 antigen can bind to human erythrocytes. Acta Biochimica Polonica, 2012, 59, 685-91.	0.5	2
35	Curing Hemophilia: Repeated Treatments versus a One-Off Fix. Molecular Therapy, 2020, 28, 1229-1230.	8.2	1
36	Missing the sweet spot: one of the two N-glycans on human Gb3/CD77 synthase is expendable. Glycobiology, 2021, 31, 1145-1162.	2.5	1

#	Article	IF	Citations
37	Can mutations in the gene encoding transcription factor EKLF (Erythroid KrÃ¼ppel-Like Factor) protect us against infectious and parasitic diseases?. Postepy Higieny I Medycyny Doswiadczalnej, 2016, 70, 1068-1086.	0.1	1
38	Revisiting the "Danger Theory": Toll-like Receptor 9 Stimulation Triggers Activation of Conventional CD8Î±+ and Plasmacytoid Dendritic Cells En Route to Enhancing FVIII Inhibitor Formation. Blood, 2020, 136, 1-1.	1.4	1
39	Two Paralogous Gb3/CD77 Synthases in Birds Show Different Preferences for Their Glycoprotein and Glycosphingolipid Substrates. International Journal of Molecular Sciences, 2021, 22, 9761.	4.1	0
40	Hepatitis C and bleeding disorders in Europe. The Journal of Haemophilia Practice, 2018, 5, 50-65.	0.4	0
41	Toll-like Receptor 9 Activation Accelerates Inhibitor Formation in Response to Factor VIII. Blood, 2019, 134, 1113-1113.	1.4	0
42	Helper T Cell Response to Factor VIII In Vivo Requires Several Anatomically Distinct Types of Antigen Presenting Cells. Blood, 2021, 138, 440-440.	1.4	0
43	Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial. Blood, 2021, 138, 3972-3972.	1.4	0
44	Factor IX Delivery to the Skin Primes Inhibitor Formation and Sensitizes Hemophilia B Mice to Systemic Factor IX Administration. Blood, 2021, 138, 3194-3194.	1.4	0
45	Alternative Approaches to Oral Tolerance Induction to Factor FVIII. Blood, 2020, 136, 8-9.	1.4	0